Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S062 - New Emerging Therapies

Monday, February 19; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify new treatments and therapies that are either available now or will be available in the near future to treat psoriasis, acne, rosacea, hair loss, atopic dermatitis, nonmelanoma skin cancer, as well as infections of the skin.
  • Evaluate present and future therapies for prevention and treatment of scars
  • Develop treatment algorithms to expand our options for minimally invasive cosmetic dermatology.


This session is designed to present new emerging therapies that are available either now or in the near future for both common dermatologic conditions, including psoriasis, atopic dermatitis, acne, rosacea, infections of the skin and nonmelonoma skin cancer, as well as scar therapy and minimally invasive cosmetic procedures.


  • Ablon, Glynis R., MD: Eclipse Medical – Speaker/Faculty Education(H); EndyMed Medical Inc. USA – Speaker/Faculty Education(H); Galderma Laboratories, L.P. – A(H); Lifes2Good – I(Grants/Research Funding); Neothetics – I(Grants/Research Funding); ThermiAesthetics – Speaker/Faculty Education(H); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding);
  • Berman, Brian, MD, PhD: Aclaris Therapeutics, Inc. – A(H), C(H); Actavis – I(Grants/Research Funding); AiViva BioPharma, Inc. – C(H); Allergan, Inc. – I(Grants/Research Funding); Allos – A(H); Almirall – A(H); Amira Pharmaceuticals – C(H); Anacor Pharmaceuticals, Inc. – A(H), I(Grants/Research Funding); Bayer Pharmaceuticals – SP(H); Berg Pharma, LLC – A(ST), C(H); Biofrontera AG – C(H); C & H Scientific, LLC – A(H); Capstone Therapeutics Corp. – C(H); Celumigen Pharmaceuticals, Inc. – B(SO), C(H), C(SO); Centocor Ortho Biotech Inc. – C(H), SP(H); CHS Pharma – A(ST); Clark Pharmaceuticals, LLC – C(H); Crescita Therapeutics Inc. – C(H); Dermira – A(H), A(SO); Doak – A(H); Dr. Tattoff – A(H), A(SO); DUSA Pharmaceuticals, Inc – A(H); DUSA Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding); Excaliard Pharmaceuticals, Inc. – C(H); Exeltis – C(H), I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – C(H); Graceway Pharmaceuticals, LLC – SP(H); Halscion – A(H); Klara/Goderma, Inc. – C(SO); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – A(H), SP(H); Liquidia Technologies, Inc. – C(H); Medicis Pharmaceutical Corporation – A(H), SP(H); Medimetriks Pharmaceuticals, Inc. – C(H); MediWound – C(H); Menlo Therapeutics – A(H); Merz Pharmaceuticals, LLC – A(H), Speaker/Faculty Education(H); Novan – C(H); Novartis Pharmaceuticals Corp. – SP(H); Oculus innovative Sciences, Inc. – C(SO); Onset Therapeutics – A(H), SP(H); Peplin Inc. – A(H), C(H); Pharmaderm – A(H); Pulse Biosciences – C(H); Realm Therapeutics – C(H); RXi Pharmaceuticals Corporation – I(NC); sanofi-aventis – A(H), SP(H); Seattle Genetics – A(H); Sensus Healthcare – A(H); Sirnaomics, Inc. – C(H); Smith & Nephew – A(H); Sol-Gel Technologies – C(H); Stiefel a GSK company – A(H), SP(H); Tigercat Pharma, Inc – I(Grants/Research Funding); TopMD – A(ST), C(H); Valeant Pharmaceuticals International – SP(H);
  • Berson, Diane S., MD: Aclaris Therapeutics Inc. – C(H); Allergan, Inc – C(H); Bayer – A(H); Galderma Laboratories, L.P. – A(H); La Roche-Posay Laboratoire Pharmaceutique – A(H); Procter & Gamble Company – C(H); Revance Therapeutics, Inc. – A(H); Sienna Biopharmaceuticals – A(H); Sinclair Pharma – A(H); Skinfix, Inc. – A(H); Taro Pharm – A(H); TopMD – C(H);
  • Cohen, David Eric, MD: Bickel Biotechnology – B(SO); Dermira – B(Fees), B(ST); Facilitation of International Dermatology Education – C(H); Ferndale Laboratories, Inc. – C(H); Medimetriks Pharmaceuticals, Inc. – C(H), C(SO); Novartis – C(H);
  • Goldberg, David J., MD, JD: Allergan, Inc. – I(Grants/Research Funding); Almirall – C(S); Aquavit Pharmaceuticals – E(SO); Cutera, Inc. – I(Grants/Research Funding); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); Novan – I(Grants/Research Funding); Sebcaia, Inc – I(Grants/Research Funding); Sensus Healthcare – C(Fees); Sienna Biopharmaceuticals – I(Grants/Research Funding); Stratapharma – I(Grants/Research Funding); Syneron, Inc. – I(Grants/Research Funding), SP(H);
  • Kircik, Leon H., MD: 3M Pharmaceuticals – I(Grants/Research Funding), SP(H); Abbott Laboratories – SP(H); Ablynx – I(Grants/Research Funding); Acambis – I(Grants/Research Funding); Allergan, Inc – A(H), C(H), I(H), SP(H); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding), SP(H); Astellas Pharma US, Inc – I(Grants/Research Funding), SP(H); Asubio Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Biogen – A(H); Biolife – I(Grants/Research Funding); Biopelle, Inc. – I(Grants/Research Funding); Breckinridge Pharma – I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); ColBar LifeScience Ltd. – A(H), C(H); CollaGenex Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding), SP(H); Connetics Corporation – A(H), C(H), I(Grants/Research Funding); Coria Laboratories – I(Grants/Research Funding); Dermik Laboratories, a business of sanofi-aventis U.S. LLC – SP(H); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Embil Pharmaceuticals, Co., Ltd – SP(H); EOS – A(H); Ferndale Laboratories, Inc. – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – A(H), C(H), I(Grants/Research Funding); Isdin – A(H); Johnson & Johnson Consumer Products Company – A(H), C(H), I(Grants/Research Funding), SH(ST), SP(H); Laboratory Skin Care, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding), SP(H); Medical International Technologies – C(H); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc – C(H); Merck Serono – SP(H); Merz Pharmaceuticals, LLC – C(H); NanoBio Corporation – A(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Nucryst – I(Grants/Research Funding); Obagi Medical Products – I(Grants/Research Funding); Onset Dermatologics – I(Grants/Research Funding), SP(H); Othro Dermatologics – A(H), C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – I(Grants/Research Funding); Pharmaderm – I(Grants/Research Funding), SP(H); Promius Pharma, LLC – A(H), C(H), I(Grants/Research Funding); PuraCap Pharmaceutical – C(H); QLT Inc. – I(H); SkinMedica, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); Stiefel a GSK company – A(H), C(H), I(Grants/Research Funding), SP(H); Sun Pharmaceutical Industries Ltd. – A(H); TolerRx – I(Grants/Research Funding); Triax Pharmaceuticals, LLC – C(H), I(Grants/Research Funding), SP(H); Valeant Pharmaceuticals International – A(H), C(H), I(Grants/Research Funding), SP(H); Warner Chilcott – A(H), I(Grants/Research Funding), SP(H); Xenoport, Inc. – I(Grants/Research Funding); Zalicus – I(Grants/Research Funding);
  • Nestor, Mark S., MD, PhD: Aclaris Therapeutics, Inc. – A(H); Actavis – I(Grants/Research Funding); Aerolase – A(H); Allergan, Inc – I(Grants/Research Funding); Almirall – A(H), C(H); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer HealthCare – A(H), C(H); Bioderma – A(H); Biofrontera AG – A(H), I(Grants/Research Funding); BirchBioMed – A(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Castle Biosciences, Inc – A(H); Clarisonic – A(H); Croma-Pharma GmbH Austria – I(Grants/Research Funding); Cynova Laboratories – I(Grants/Research Funding); Demira – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Essence Novel – A(H); Evolus, Inc. – I(Grants/Research Funding); Ferndale Laboratories, Inc. – A(H), C(H), I(Grants/Research Funding); I.F.C., S.A. – I(Grants/Research Funding), SP(H); IntraDerm Pharmaceuticals – A(H), I(Grants/Research Funding); ISDIN – A(H); Johnson & Johnson Pharmaceutical Research & Development – I(Grants/Research Funding); Johnson and Johnson – A(H), C(H); Leo Pharma Inc – I(Grants/Research Funding); Leo Pharma Inc. – A(H); MC2 Therapeutics – I(Grants/Research Funding); Sensus Healthcare – A(H), C(H), Speaker/Faculty Education(H); Sinclair Pharma – A(H), C(H), I(Grants/Research Funding); SiSaf, Ltd. – I(Grants/Research Funding); Sonoma Pharmaceuticals – I(Grants/Research Funding); Stratapharma – A(H); Strathspey Crown – SH(NC); ThermiAesthetics – A(H), C(H), SP(H);
  • Rosen, Theodore, MD: Medimetriks Pharmaceuticals, Inc. – C(H); Menlo Therapeutics – A(H); Valeant Pharmaceuticals International – C(H);
Monday, February 19
1:00 PM
Dr. Nestor / Introduction
1:04 PM
Dr. Kircik / New and Emerging Therapies for Psoriasis with Q&A
1:26 PM
Dr. Rosen / New and Emerging Therapies in Infection of the Skin with Q&A
1:48 PM
Dr. Berson / New and Emerging Therapies in Acne and Rosacea with Q&A
2:10 PM
Dr. Ablon / New and Emerging Therapies for Hair Loss with Q&A
2:32 PM
Dr. Cohen / New and Emerging Therapies for Atopic Dermatitis with Q&A
2:54 PM
Dr. Goldberg / New and Emerging Therapies for NMSC with Q&A
3:16 PM
Dr. Berman / New and Emerging Therapies for Scars with Q&A
3:38 PM
Dr. Nestor / New and Emerging Therapies in Aesthetic Dermatology with Q&A
Event Details
  • Date
    Monday, February 19
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 29B
  • CME Credits
  • Type
  • Mark S. Nestor, MD, PhD, FAAD
  • Brian Berman, MD, PhD, FAAD
  • David Eric Cohen, MD, FAAD
  • David J. Goldberg, MD, JD, FAAD - Handout
  • Diane S. Berson, MD, FAAD
  • Glynis R. Ablon, MD, FAAD
  • Leon H. Kircik, MD, FAAD - Handout
  • Theodore Rosen, MD, FAAD - Handout